Literature DB >> 8940410

Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene.

Y Zhao1, V R Agarwal, C R Mendelson, E R Simpson.   

Abstract

In the present report, we show that prostaglandin (PG) E2 is the most potent factor which stimulates aromatase expression via cyclic AMP and promoter II. PGE2 acts via EP1 and EP2 receptor subtypes to stimulate both the PKC and PKA pathways. The combined stimulation of both of these pathways results in maximal expression of promoter II-specific CYP19 transcripts. Since PGE2 is a major secretory product both of breast tumor epithelial cells and fibroblasts, as well as of macrophages infiltrating the tumor site, then this could be the mechanism whereby estrogen biosynthesis is stimulated in breast sites adjacent to a tumor, leading in turn to increased growth and development of the tumor itself.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940410     DOI: 10.1210/endo.137.12.8940410

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  110 in total

Review 1.  Aromatase, breast cancer and obesity: a complex interaction.

Authors:  Serdar E Bulun; Dong Chen; Irene Moy; David C Brooks; Hong Zhao
Journal:  Trends Endocrinol Metab       Date:  2011-12-12       Impact factor: 12.015

Review 2.  Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

Authors:  Sarah C Baumgarten; Jonna Frasor
Journal:  Mol Endocrinol       Date:  2012-02-02

3.  Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.

Authors:  E H Allott; C-K Tse; A F Olshan; L A Carey; P G Moorman; M A Troester
Journal:  Breast Cancer Res Treat       Date:  2014-08-24       Impact factor: 4.872

Review 4.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II.

Authors:  A Heather Eliassen; Wendy Y Chen; Donna Spiegelman; Walter C Willett; David J Hunter; Susan E Hankinson
Journal:  Arch Intern Med       Date:  2009-01-26

6.  Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Authors:  Kathrin Strasser-Weippl; Michaela J Higgins; Judith-Anne W Chapman; James N Ingle; George W Sledge; George T Budd; Matthew J Ellis; Kathleen I Pritchard; Mark J Clemons; Tanja Badovinac-Crnjevic; Lei Han; Karen A Gelmon; Manuela Rabaglio; Catherine Elliott; Lois E Shepherd; Paul E Goss
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

Review 7.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

8.  Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study.

Authors:  Christopher G Slatore; David H Au; Alyson J Littman; Jessie A Satia; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

9.  The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cells.

Authors:  Bin Dong; Fumio Matsumura
Journal:  Mol Endocrinol       Date:  2009-01-15

Review 10.  Impact of obesity on mammary gland inflammation and local estrogen production.

Authors:  Kristy A Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-06-17       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.